Last reviewed · How we verify
Dopram (DOXAPRAM)
Dopram (DOXAPRAM) is a small molecule respiratory stimulant that targets the cytochrome P450 2D6 enzyme. It was originally developed by HIKMA MAPLE and is now owned by Hikma. FDA approved in 1965, it is used to treat decreased respiratory function and post-anesthesia respiratory depression. As an off-patent medication, it is available as a generic from multiple manufacturers. Key safety considerations include its potential to cause arrhythmias and other cardiovascular effects.
At a glance
| Generic name | DOXAPRAM |
|---|---|
| Sponsor | Hikma |
| Drug class | Respiratory Stimulant |
| Target | Cytochrome P450 2D6 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1965 |
Approved indications
- Decreased respiratory function
- Post-Anesthesia Respiratory Depression
Common side effects
- mild to moderate increase in blood pressure
- decrease in hemoglobin
- decrease in hematocrit
- decrease in red blood cell count
- further decrease in WBC
- hemolysis with rapid infusion
- elevation of BUN
- albuminuria
- urinary retention
- stimulation of urinary bladder with spontaneous voiding
- nausea
- vomiting
Key clinical trials
- Doxapram Administration on Diaphragmatic Excursion in Mechanically Ventilated Patients With Chronic Obstructive Pulmonary Disease Undergoing Spontaneous Breathing Trial
- Study to Investigate the Safety, Tolerability and Pharmacokinetics of QEV-817 Oral Suspension (PHASE1)
- Doxapram Therapy in Preterm Infants (DOXA Trial) (PHASE3)
- Population PK/PD of Off Label Drugs in Premature Neonates
- The Effect of Doxapram Versus Theophylline on Diaphragmatic Function (NA)
- Staccato Alprazolam in Panic Attack (PHASE2)
- Dosing Chart for Calculating the First Dose of Doxapram in Premature Infants (PHASE4)
- The Effect and Mechanism of Respiratory Stimulant Doxapram on Facilitating Emergence (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dopram CI brief — competitive landscape report
- Dopram updates RSS · CI watch RSS
- Hikma portfolio CI